Pacira BioSciences (PCRX) Inventory (2010 - 2026)

Pacira BioSciences' Inventory history runs 17 years deep, the most recent figure standing at $150.4 million for Q1 2026.

• On a quarterly basis, Inventory rose 12.42% year-over-year to $150.4 million in Q1 2026; TTM through Mar 2026 was $150.4 million, a 12.42% increase from a year earlier, with the FY2025 full-year figure at $152.9 million, up 22.02% from the prior year.
• Inventory eased to $150.4 million in Q1 2026 per PCRX's latest filing, from $152.9 million in the prior quarter.
• Across five years, Inventory topped out at $157.7 million in Q3 2025 and bottomed at $92.1 million in Q2 2023.
• The 5-year median for Inventory is $103.7 million (2022), against an average of $115.5 million.
• Across the five-year window, Inventory jumped 60.45% in 2022 and dropped 10.31% in 2023, its largest moves.
• Year by year, Inventory stood at $96.1 million in 2022, then rose by 8.63% to $104.4 million in 2023, then increased by 20.06% to $125.3 million in 2024, then gained by 22.02% to $152.9 million in 2025, then slipped by 1.63% to $150.4 million in 2026.
• Per Business Quant, the three latest PCRX Inventory figures stand at $150.4 million (Q1 2026), $152.9 million (Q4 2025), and $157.7 million (Q3 2025).